Pharmacological studies and pharmacokinetic modelling to support the development of interventions targeting ecological reservoirs of Lyme disease

Jérôme Pelletier,Catherine Bouchard,Cécile Aenishaenslin,Francis Beaudry,Nicholas H. Ogden,Patrick A. Leighton,Jean-Philippe Rocheleau
DOI: https://doi.org/10.1038/s41598-024-63799-x
IF: 4.6
2024-06-13
Scientific Reports
Abstract:The development of interventions targeting reservoirs of Borrelia burgdorferi sensu stricto with acaricide to reduce the density of infected ticks faces numerous challenges imposed by ecological and operational limits. In this study, the pharmacokinetics, efficacy and toxicology of fluralaner were investigated in Mus musculus and Peromyscus leucopus mice, the main reservoir of B . burgdorferi in North America. Fluralaner showed rapid distribution and elimination, leading to fast plasma concentration (C p ) depletion in the first hours after administration followed by a slow elimination rate for several weeks, resulting in a long terminal half-life. Efficacy fell below 100% while C p (± standard deviation) decreased from 196 ± 54 to 119 ± 62 ng/mL. These experimental results were then used in simulations of fluralaner treatment for a duration equivalent to the active period of Ixodes scapularis larvae and nymphs. Simulations showed that doses as low as 10 mg/kg have the potential to protect P . leucopus against infestation for a full I . scapularis active season if administered at least once every 7 days. This study shows that investigating the pharmacology of candidate acaricides in combination with pharmacokinetic simulations can provide important information to support the development of effective interventions targeting ecological reservoirs of Lyme disease. It therefore represents a critical step that may help surpass limits inherent to the development of these interventions.
multidisciplinary sciences
What problem does this paper attempt to address?
The paper aims to address the challenges in developing interventions for ecological reservoir hosts of Lyme disease. Specifically, the study focuses on using the acaricide fluralaner to reduce the density of ticks infected with the Lyme disease pathogen (Borrelia burgdorferi sensu stricto). The main objectives of the study include: 1. **Pharmacokinetics, Efficacy, and Toxicology Studies**: Investigate the pharmacokinetic properties, efficacy, and potential toxicity of fluralaner in two primary Lyme disease reservoir hosts—house mice (Mus musculus) and white-footed mice (Peromyscus leucopus). 2. **Simulating Fluralaner Treatment Regimens**: Based on experimental results, use pharmacokinetic modeling to predict the efficacy of fluralaner in white-footed mice at different doses and administration frequencies, to assess whether these regimens can protect white-footed mice from tick infestations throughout the black-legged tick (Ixodes scapularis) activity season. 3. **Evaluating the Impact of Drug Characteristics on Interventions**: Study how the pharmacological properties of fluralaner influence the design and practical limitations of interventions targeting Lyme disease reservoir hosts. Through these studies, the authors hope to provide critical information and support for developing effective Lyme disease control strategies targeting ecological reservoir hosts.